ALK and non-small cell lung carcinoma: Crizotinib is the first ALK-targeted therapy approved by the US Food and Drug Administration (FDA) for patients with ALK-rearranged NSCLC and is also a standard first-line treatment for advanced ALK-positive NSCLC in many countries, including China (10, 15).